Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 6/2008

01-06-2008 | Letter to the Editor

High-dose melphalan followed by a second bone marrow transplantation in early relapse of acute myeloid leukemia after bone marrow transplantation in children

Authors: Adrian Tempescul, Jean-Christophe Ianotto, Jean-Richard Eveillard, Gaelle Guillerm, Christian Berthou, Veronique Marion, Marc De Braekeleer

Published in: Annals of Hematology | Issue 6/2008

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Schmid C et al (2007) Donor lymphocyte infusion in the treatment of first haematological relapse in allogeneic stem-cell transplantation in adults with acute myeloid leukaemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25(31):4938–4945 NovPubMedCrossRef
2.
Bug G et al (2005) High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation. Ann Hematol 84(11):748–754 OctPubMedCrossRef
3.
de Lima M et al (2000) High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant 26(3):333–338 AugPubMedCrossRef
Metadata
Title
High-dose melphalan followed by a second bone marrow transplantation in early relapse of acute myeloid leukemia after bone marrow transplantation in children
Authors
Adrian Tempescul
Jean-Christophe Ianotto
Jean-Richard Eveillard
Gaelle Guillerm
Christian Berthou
Veronique Marion
Marc De Braekeleer
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 6/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-007-0432-1

Other articles of this Issue 6/2008

Annals of Hematology 6/2008 Go to the issue

Letter to the Editor

Primary cardiac onset of disseminated Burkitt’s lymphoma

Review Article

Simultaneous expression of Oct4 and genes of three germ layers in single cell-derived multipotent adult progenitor cells

Letter to the editor

Acute renal failure due to hypercalcemia-related nephrocalcinosis in a patient of non-Hodgkin’s lymphoma featuring swelling of bilateral kidneys

Original Article

Tissue factor procoagulant activity of plasma microparticles in patients with cancer-associated disseminated intravascular coagulation

Letter to the Editor

Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine

Original Article

High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin’s lymphoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits